Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: Long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

European Heart Journal

Volumn 31, Issue 2, 2010, Pages 177-186

  Stenestrand, Ulf ^a   James, Stefan K ^b,c   Lindbäck, Johan ^b   Fröbert, Ole ^c   Carlsson, Jörg ^c   Scherstén, Fredrik ^c   Nilsson, Tage ^c   Lagerqvist, Bo ^b,c  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^c Department of Cardiology ^*  (Sweden)

Author keywords

Diabetes mellitus; Drug eluting stent; Mortality; Myocardial infarction; Outcome; Percutaneous coronary intervention; Revascularization

Indexed keywords

ADULT; AGED; ARTICLE; BARE METAL STENT; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESTENOSIS; RISK ASSESSMENT; RISK FACTOR;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CORONARY RESTENOSIS; DIABETIC ANGIOPATHIES; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; REGISTRIES; RISK FACTORS; STENTS; SWEDEN;

EID: 74549191936     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp424     Document Type: Article

References (30)

1. Hoffmann R, Stellbrink E, Schroder J, Grawe A, Vogel G, Blindt R, Kelm M, Radke PW. Impact of the metabolic syndrome on angiographic and clinical events after coronary intervention using bare-metal or sirolimus-eluting stents. Am J Cardiol 2007;100:1347-1352.
2. Kumar R, Lee TT, Jeremias A, Ruisi CP, Sylvia B, Magallon J, Kirtane AJ, Bigelow B, Abrahamson M, Pinto DS, Ho KK, Cohen DJ, Carrozza JP Jr, Cutlip DE. Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients. Am J Cardiol 2007;100:1187-1191.
3. Mehta RH, Honeycutt E, Shaw LK, Milano CA, Smith PK, Harrington RA, Sketch MH Jr. Clinical and angiographic correlates of short-and long-term mortality in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007; 100:1538-1542.
4. Kirtane AJ, Ellis SG, Dawkins KD, Colombo A, Grube E, Popma JJ, Fahy M, Leon MB, Moses JW, Mehran R, Stone GW. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J Am Coll Cardiol 2008;51:708-715.
5. King SB 3rd. Is surgery preferred for the diabetic with multivessel disease? Surgery is preferred for the diabetic with multivessel disease. Circulation 2005;112: 1500-1507; discussion 1514-11505
6. Roffi M, Topol EJ. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2004;25: 190-198.
7. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabate M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schomig A. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-1039.
8. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-948. (Pubitemid 47393576)
9. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
10. Farb A, Boam AB. Stent thrombosis redux\-the FDA perspective. N Engl J Med 2007;356:984-987.
11. Maisel WH. Unanswered questions\-drug-eluting stents and the risk of late thrombosis. N Engl J Med 2007;356:981-984.
12. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S, Hellige G, Tsuchida K, Morger C, Boersma E, Kukreja N, Meier B, Serruys PW, Windecker S. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008; 52:1134-1140.
13. Angiolillo DJ, Bernardo E, Sabate M, Jimenez-Quevedo P, Costa MA, Palazuelos J, Hernandez-Antolin R, Moreno R, Escaned J, Alfonso F, Banuelos C, Guzman LA, Bass TA, Macaya C, Fernandez-Ortiz A. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007;50:1541-1547.
14. Erlinge D, Varenhorst C, Braun OO, James S, Winters KJ, Jakubowski JA, Brandt JT, Sugidachi A, Siegbahn A, Wallentin L. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008;52:1968-1977.
15. Jimenez-Quevedo P, Sabate M, Angiolillo DJ, Alfonso F, Hernandez-Antolin R, SanMartin M, Gomez-Hospital JA, Banuelos C, Escaned J, Moreno R, Fernandez C, Fernandez-Aviles F, Macaya C. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. Eur Heart J 2007;28: 1946-1952.
16. Maeng M, Jensen LO, Kaltoft A, Hansen HH, Bottcher M, Lassen JF, Thayssen P, Krusell LR, Rasmussen K, Pedersen L, Sorensen HT, Johnsen SP, Thuesen L. Comparison of stent thrombosis, myocardial infarction, and mortality following drug-eluting versus bare-metal stent coronary intervention in patients with diabetes mellitus. Am J Cardiol 2008;102:165-172.
17. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356:989-997.
18. Flynn MR, Barrett C, Cosio FG, Gitt AK, Wallentin L, Kearney P, Lonergan M, Shelley E, Simoons ML. The Cardiology Audit and Registration Data Standards (CARDS), European data standards for clinical cardiology practice. Eur Heart J 2005;26:308-313.
19. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-1019.
20. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
21. Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, Hopkins R, Tarride JE, Blackhouse G, Lazzam C, Cohen EA, Goeree R. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007;357:1393-1402.
22. Brunner-La Rocca HP, Kaiser C, Bernheim A, Zellweger MJ, Jeger R, Buser PT, Osswald S, Pfisterer M. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitats Trial (BASKET): an 18-month analysis. Lancet 2007;370:1552-1559.
23. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. Br Med J 1999;1492-1495.
24. RDevelopmentCoreTeam. A Language and Environment for Statistical Computing. Vienna, Austria: R-Foundation for Statistical Computing; 2006. ISBN 3-900051-07-0. http://www.R-project.org.
25. Daemen J, Tanimoto S, Garcia-Garcia HM, Kukreja N, van de Sande M, Sianos G, de Jaegere PP, van Domburg RT, Serruys PW. Comparison of three-year clinical outcome of sirolimus-and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am J Cardiol 2007;99:1027-1032.
26. Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, van der Wieken LR, Tijssen JG, Rensing BJ, Patterson M. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006;355:1105-1113.
27. Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, Bernheim A, Zutter A, Zellweger M, Grize L, Pfisterer ME. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005;366:921-929.
28. Garg P, Normand SL, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, Varma MR, Zhou Z, Mauri L. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry. Circulation 2008;118:2277-2285.
29. Lemos PA, Hoye A, Goedhart D, Arampatzis CA, Saia F, van der Giessen WJ, McFadden E, Sianos G, Smits PC, Hofma SH, de Feyter PJ, van Domburg RT, Serruys PW. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 2004;109:1366-1370.
30. Stone GW. HORIZONS AMI\-a prospective, randomized comparison of paclitaxel-eluting TAXUS stents vs. bare metal stents during primary angioplasty in acute myocardial infarction. Late Breaking Trials at TCT 2008.